EANS-Adhoc: - Marseille-Kliniken Group disposing of its rehabilitation division - The transaction includes all rehabilitation clinics with a total of 1,269 beds - Sale generates a book gain in a low

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Disposing of business division

21.04.2010

Berlin, 21 April 2010. Marseille-Kliniken Group (Prime Standard, ISIN
DE 0007783003, MKA) has, as already announced some time ago, disposed
of all rehabilitation clinic operations, thereby discontinuing the
Group´s rehabilitation business. The closing of the sale depends on
the approval of the annual general meeting of Karlsruhe Sanatorium AG
as well as the lessor´s consent. This is to be completed by the
beginning of May 2010. Capacities of 1,269 beds at seven locations in
Germany are being sold.

The transaction is impacting the investments in the rehabilitation
clinics operated by Karlsruhe Sanatorium AG, a subsidiary of
Marseille-Kliniken AG. It includes the Gotthard-Schettler-Klinik and
REHA-Klinik Sigmund Weil, both located in Bad Schönborn, the
specialist clinic for mental conditions Ortenau in Zell am
Harmersbach, the clinic in Bad Herrenalb, the specialist clinic for
psychosomatic conditions Schömberg as well as the psychosomatic
clinic Kinzigtal in Gengenbach. Marseille-Kliniken AG also disposed
of its investments in the rehabilitation companies Algos Fachklinik
in Bad Klosterlausnitz, the sports and rehabilitation center Harz and
Teufelsbad specialist clinic Blankenburg, both in Blankenburg/Harz.
The clinic locations are each operated as limited companies (GmbH)
and their shares were sold as part of this transaction.

In return, Marseille-Kliniken Group will be recording a significant
book gain amounting to a lower double-digit EUR million scope. Both
parties agreed not to disclose the exact purchase amount involved.

Marseille-Kliniken Group is making the sale to a joint venture held
by funds which financial investor AUCTUS Capital Partners AG
consults, and the existing management team around CEO Berthold Müller
and Medical Director Professor Dr. Ulrich T. Egle and Professor Dr.
Bernd E. Fromm. AUCTUS is Germany´s leading SME investment company
and commands considerable expertise in the field of healthcare.

The Rehabilitation division is profitable, it has not been part of
the core business of Marseille-Kliniken Group in the recent past. The
company has been reviewing a sale of the division for some time as a
result. Generated inflows are to be invested in further developing
the Care core business.

End of ad hoc release

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Hillermann Consulting

Christian Hillermann

Investor Relations for Marseille-Kliniken AG

Poststraße 14/16

20354 Hamburg

Germany

Tel.: +49-(0)40 / 320 279-10

Fax: +49-(0)40 / 320 279-114

www.hillermann-consulting.de

Marseille-Kliniken AG

Dr. Ute Buchheim

Friedrich-Ebert-Str. 65

33330 Gütersloh

Germany

Tel.: +49-(0)5241 / 90 39-35

Fax: +49-(0)5241 / 90 39-39

www.marseille-kliniken.com

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hamburg / regulated dealing